SMU-L11-R

SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8+T cells. SMU-L11-R shows potential in colorectal cancer studies[1].

Product Specifications

CAS Number

[3040320-18-8]

Target

ERK; IKK; Interleukin Related; MyD88; p38 MAPK; TNF Receptor; Toll-like Receptor (TLR)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Field of Research

Cancer; Inflammation/Immunology

Smiles

NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3C[C@@H]4COCC4

Molecular Formula

C19H24N4O

Molecular Weight

324.42

References & Citations

[1]Pan Y, et al. Imidazoloquinoline optical isomers as TLR7 selective agonists promote macrophage activation for cancer immunotherapy. Bioorg Chem. Published online October 13, 2025.